Zai Lab (ZLAB) said late Wednesday that China's National Medical Products Administration has accepted its marketing application for Tivdak, a therapy for treating certain patients with cervical cancer.

The company said the application is supported by a phase 3 study in which Tivdak demonstrated a 45% reduction in the risk of death compared to chemotherapy in the China subpopulation that had received prior standard systemic therapies.